Literature DB >> 30551165

Increased Incidence Rate of Hypothyroidism After Iodine Fortification in Denmark: A 20-Year Prospective Population-Based Study.

Mads Petersen1, Nils Knudsen2, Allan Carlé1, Stig Andersen3, Torben Jørgensen4,5,6, Hans Perrild2, Lars Ovesen7, Lone Banke Rasmussen2, Betina Heinsbæk Thuesen4, Inge Bülow Pedersen1.   

Abstract

OBJECTIVE: To monitor the impact of a cautious iodine fortification (IF) on the incidence of overt hypothyroidism in two subpopulations with different levels of preexisting iodine deficiency (ID).
DESIGN: A 20-year (1997 to 2016) prospective population-based study identified all new cases of diagnosed overt biochemical hypothyroidism in two open cohorts: a western cohort with moderate ID (n = 309,434; 1 January 1997) and an eastern cohort with mild ID (n = 224,535; 1 January 1997). A diagnostic algorithm was applied to all thyroid function tests performed within the study areas, and possible new cases were verified individually. Mandatory IF of salt was initiated in mid-2000 (13 ppm). The current study is a part of the DanThyr study.
RESULTS: At baseline, standardized incidence rates (SIRs) of hypothyroidism were 32.9 and 47.3/100.000/y in the cohorts with moderate and mild ID, respectively. The SIR of hypothyroidism increased significantly in both cohorts after implementing mandatory IF, with peak values of 150% in 2014 to 2016 for the moderate ID cohort and 130% in 2004 to 2005 for the mild ID cohort. Significant increases in SIR were seen among the young and middle-aged participants of both cohorts, whereas no changes were seen among the elderly participants (≥60 years). The follow-up period for the mildly iodine-deficient cohort was restricted up to and including 2008.
CONCLUSION: The cautious initiation of the IF program in Denmark caused a sustained increase in hypothyroidism incidence among subjects residing in areas of moderate and mild ID but only among the young and middle-aged participants.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30551165     DOI: 10.1210/jc.2018-01993

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany.

Authors:  Monika Schaffner; Ursula Rochau; Nikolai Mühlberger; Annette Conrads-Frank; Vjollca Qerimi Rushaj; Gaby Sroczynski; Eftychia Koukkou; Betina Heinsbaek Thuesen; Henry Völzke; Wilhelm Oberaigner; Uwe Siebert
Journal:  Endocr Connect       Date:  2021-01       Impact factor: 3.335

2.  Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society.

Authors:  Tereza Planck; Mikael Lantz; Petros Perros; Enrico Papini; Roberto Attanasio; Endre V Nagy; Laszlo Hegedüs
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-06       Impact factor: 5.555

3.  Reference Intervals for Serum Thyroid-Stimulating Hormone Based on a Recent Nationwide Cross-Sectional Study and Meta-Analysis.

Authors:  Xichang Wang; Yongze Li; Xiaodan Zhai; Haoyu Wang; Fan Zhang; Xiaotong Gao; Shengyu Liu; Weiping Teng; Zhongyan Shan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-01       Impact factor: 5.555

4.  Register-based information on thyroid diseases in Europe: lessons and results from the EUthyroid collaboration.

Authors:  Line Tang Møllehave; Marie Holm Eliasen; Ieva Strēle; Allan Linneberg; Rodrigo Moreno-Reyes; Ludmila B Ivanova; Zvonko Kusić; Iris Erlund; Till Ittermann; Endre V Nagy; Ingibjorg Gunnarsdottir; Jonathan Eli Arbelle; Aaron Milton Troen; Valdis Pīrāgs; Lisbeth Dahl; Alicja Hubalewska-Dydejczyk; Malgorzata Trofimiuk-Müldner; João Jacome de Castro; Mafalda Marcelino; Simona Gaberšček; Katja Zaltel; Manuel Puig-Domingo; Lluis Vila; Sofia Manousou; Helena Filipsson Nyström; Michael Bruce Zimmermann; Karen R Mullan; Jayne Valerie Woodside; Henry Völzke; Betina Heinsbæk Thuesen
Journal:  Endocr Connect       Date:  2022-03-10       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.